Cancer cells subvert fibroblast function to promote a growth factor enriched tumor microenvironment in endocrine therapy resistant ER plus breast cancer

被引：0
作者：
Griffiths, Jason I.
Cosgrove, Patrick A.
Castaneda, Eric Medina
Nath, Aritro
Chen, Jinfeng
Adler, Frederick R.
Chang, Jeffrey T.
Khan, Qamar J.
Bild, Andrea H.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-5693
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5693
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Neurotrophin-3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis
    Louie, E.
    Chen, X. F.
    Coomes, A.
    Ji, K.
    Tsirka, S.
    Chen, El
    ONCOGENE, 2013, 32 (35) : 4064 - 4077
  • [22] Microenvironment creates premalignant mammary tissues and therapy-resistant persistent tumor cells in breast cancer
    Gotoh, Noriko
    CANCER SCIENCE, 2023, 114 : 800 - 800
  • [23] Endocrine agents promote adverse responses in ER plus breast cancer cells through a mechanism involving PELP1
    Rees, Michael
    Smith, Chris
    Barrett-Lee, Peter
    Hiscox, Steve
    CANCER RESEARCH, 2020, 80 (04)
  • [24] The effect of fibroblast growth factor receptor inhibition on the growth of breast cancer cells
    Kahkonen, T. E.
    Toriseva, M.
    Ivaska, K. K.
    Harkonen, P.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S202 - S202
  • [25] Breast cancer bone metastases Combination therapy targeting cancer cells and the tumor microenvironment
    de Kluyver, Rachel L.
    Sayers, Thomas J.
    CANCER BIOLOGY & THERAPY, 2010, 9 (07) : 551 - 553
  • [26] Methylparaben stimulates tumor initiating cells in ER plus breast cancer models
    Lillo, M. Angeles
    Nichols, Cydney
    Perry, Chanel
    Runke, Stephanie
    Krutilina, Raisa
    Seagroves, Tiffany N.
    Miranda-Carboni, Gustavo A.
    Krum, Susan A.
    JOURNAL OF APPLIED TOXICOLOGY, 2017, 37 (04) : 417 - 425
  • [27] Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER plus breast cancer
    Ellis, Matthew J.
    BREAST, 2017, 34 : S104 - S107
  • [28] Re-sensitising endocrine resistant ER plus breast cancer by targeting epigenetic modifying enzymes
    Borchert, G.
    Casciello, F.
    Kelly, G.
    Baxter, E.
    Gannon, F.
    Lee, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [29] The role of HER2 mutations in resistance to endocrine therapy in ER plus breast cancer
    Nayar, U.
    Cohen, O.
    Oh, C.
    Wagle, N.
    CANCER RESEARCH, 2017, 77
  • [30] Inhibition of Focal Adhesion Kinase Suppresses Adverse Features of Endocrine-Resistant Breast Cancer Cells and Improves Endocrine Response in ER plus , Endocrine-Sensitive Cells
    Hiscox, S.
    Barnfather, P.
    Hayes, E.
    Bramble, P.
    Christensen, J.
    Nicholson, R., I
    Barrett-Lee, P.
    CANCER RESEARCH, 2009, 69 (24) : 689S - 689S
12345